SCHEMBL2853408

SCHEMBL2853408

CCN(CCNS(=O)(=O)c1cccc(N)c1)c1cccc(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ MAPT P10636 4/20 0.53
▸ HPGD P15428 2/20 0.53
▸ TSHR P16473 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ GFER P55789 3/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ PRMT1 Q99873 1/20 0.49
▸ LMNA P02545 1/20 0.47
▸ GUSB P08236 1/20 0.47
▸ CYP19A1 P11511 1/20 0.46
▸ TP53 P04637 2/20 0.46
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853407 0.84 ALDH1A1 (0.52) KMT2AALDH1A1MAPTHPGDTSHR
SCHEMBL2848726 0.80 SIGMAR1 (0.58) KMT2AALDH1A1GFERPRMT1CYP19A1
SCHEMBL7897227 0.80 GFER (0.51) KMT2AALDH1A1MAPTHPGDTSHR
SCHEMBL11655314 0.79 ALDH1A1 (0.58) ALDH1A1MAPTHPGDTSHRGFER
SCHEMBL2850682 0.77 PRMT1 (0.61) KMT2AALDH1A1TSHRPRMT1LMNA
Sulfuric Acid SCHEMBL9489797 0.77 GFER (0.51) KMT2AALDH1A1MAPTHPGDTSHR
SCHEMBL11655757 0.76 CA12 (0.46) KMT2AALDH1A1MAPTHPGDTSHR
SCHEMBL2851020 0.75 USP2 (0.60) KMT2APRMT1CYP19A1CA2
SCHEMBL1565027 0.75 PRMT1 (0.73) KMT2AALDH1A1TSHRSMN1; SMN2KDM4E
SCHEMBL31174173 0.75 PRMT1 (0.73) KMT2AALDH1A1TSHRSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 — — EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 — — EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 — — US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 — — US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 KMT2A 2659/4885ALDH1A1 3589/4885MAPT 3590/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 KMT2A 2659/4885ALDH1A1 3589/4885MAPT 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback